Cargando…
Challenges and Issues of Anti-SARS-CoV-2 Vaccines
At the beginning of 2021, anti-SARS-CoV-2 vaccination campaigns had been launched in almost 60 countries with more than 500 million doses having been distributed. In addition to the few vaccines already in use, many other candidates are in preclinical phases or experimental stages in humans. Despite...
Autores principales: | Blumental, Sophie, Debré, Patrice |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8163222/ https://www.ncbi.nlm.nih.gov/pubmed/34055838 http://dx.doi.org/10.3389/fmed.2021.664179 |
Ejemplares similares
-
Development, Safety, Issues, and Challenges of the SARS-CoV-2 Vaccine
por: Matsuzaka, Yasunari, et al.
Publicado: (2023) -
A Review of SARS-CoV2: Compared With SARS-CoV and MERS-CoV
por: Zhou, Huan, et al.
Publicado: (2021) -
T Cells Targeting SARS-CoV-2: By Infection, Vaccination, and Against Future Variants
por: Nguyen, Thi H. O., et al.
Publicado: (2021) -
Challenges and issues of SARS-CoV-2 pool testing
por: Lee, Jaehyeon, et al.
Publicado: (2020) -
Challenges and issues of SARS-CoV-2 pool testing
por: Mishra, Baijayantimala, et al.
Publicado: (2020)